In these datasets, we analyzed the survival rates applying the Kaplan–Meier method by a log-rank test, which indicate that PKM2, survivin and c-Myc overexpression confer a high risk of relapse in breast cancer patients treated with tamoxifen (Figures 7A–C). This evidence concerns the gene MYC and breast cancer.